Insmed, Tercica Head To Court Over Growth Hormone Patents
This article was originally published in The Pink Sheet Daily
Executive Summary
A San Francisco federal court denied four of Insmed’s five motions for summary judgment, sending the dispute over iPlex and Increlex to trial in November.
You may also be interested in...
Tercica Will Transition Patients On iPlex To Increlex Following Insmed Patent Settlement
Insmed will no longer provide iPlex growth hormone to short stature patients but can pursue development of the drug in certain other indications.
Tercica Will Transition Patients On iPlex To Increlex Following Insmed Patent Settlement
Insmed will no longer provide iPlex growth hormone to short stature patients but can pursue development of the drug in certain other indications.
Tercica Somatuline Autogel Launch Planned For 2007 Pending NDA Approval
Tercica’s partner, Ipsen, submitted an NDA for the acromegaly treatment Oct. 30.